Abivax (ABVX) Accounts Payables (2021 - 2026)
Abivax (ABVX) posted quarterly Accounts Payables of $34.6 million for Q1 2026, down 41.89% year-over-year from $59.5 million in Q1 2025, and down 20.95% quarter-over-quarter from $43.7 million in Q4 2025.
Abivax (ABVX) Accounts Payables (2021 - 2026) Analysis & Trends
Abivax's Accounts Payables history runs 6 years deep, the most recent figure standing at $34.6 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 41.89% year-over-year to $34.6 million; the TTM figure through Mar 2026 stood at $34.6 million (down 41.89% YoY), while the FY2025 annual figure was $43.7 million, down 6.66% from the prior year.
- Accounts Payables for Q1 2026 stood at $34.6 million, down from $43.7 million in the prior quarter.
- The five-year high for Accounts Payables was $65.1 million in Q2 2025, with the low at $15.8 million in Q4 2022.
- The 5-year median for Accounts Payables is $43.7 million (2025), against an average of $42.8 million.
- The sharpest annual moves came in 2023 and 2026: Accounts Payables jumped 221.8% in 2023, then tumbled 41.89% in 2026.
- Abivax's Accounts Payables stood at $15.8 million in 2022, then surged by 221.8% to $50.8 million in 2023, then retreated by 7.83% to $46.8 million in 2024, then slipped by 6.66% to $43.7 million in 2025, then dropped by 20.95% to $34.6 million in 2026.
- Business Quant data shows ABVX's Accounts Payables at $34.6 million in Q1 2026, $43.7 million in Q4 2025, and $35.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 34.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.55 Mn |
| Dec 31, 2025 | 43.71 Mn |
| Sep 30, 2025 | 35.09 Mn |
| Jun 30, 2025 | 65.08 Mn |
| Mar 31, 2025 | 59.46 Mn |
| Dec 31, 2024 | 46.83 Mn |
| Jun 30, 2024 | 34.24 Mn |
| Dec 31, 2023 | 50.81 Mn |
| Dec 31, 2022 | 15.79 Mn |
| Dec 31, 2021 | 21.23 Mn |